Using data from the Department of Defense (DOD) Joint Trauma System (JTS), The Remdesivir Papers came to life on October 4, 2024. In the 5,400-word report by J.M. Phelps and whistleblower Daniel LeMay (a pseudonym), a question was posed: “Are U.S. military treatment facilities and others hiding, or manipulating, the deadly results of clinical trials and more [emphasis added] surrounding the controversial drug purported to be a treatment for COVID-19?”
While the report focused largely on NCT04302766, it’s time to address the “and more.” Previously referred to as a clinical trial, NCT04302766 is correctly identified as an “expanded access treatment protocol” or “Protocol S-20-01 (IND 147993).
On September 27, Rep. Clay Higgins (R-LA) sent a letter to Defense Secretary Lloyd Austin, copying the U.S. Health and Human Services Secretary, the U.S. Food and Drug Administration Commissioner, U.S. Army Medical Research and Development Command (USAMRDC) Commanding General Major General Paula C. Lodi, and others. Rep. Higgins specifically requested information regarding NCT04302766, or the “Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™).”
In response to Rep. Higgins’ letter to Defense Secretary Lloyd Austin and others, a response was provided by the Office of the Under Secretary of Defense for Personnel and Readiness, also known as USD (P&R). The response verified that “under this expanded access protocol, patients received an initial 200 milligram (mg) intravenous (IV) dose of Remdesivir on day 1, followed by once-daily 100 mg IV dose on day 2 and up to day 10.” This falls in line with the standard dosage used by trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). These include NCT04280705, NCT04401579, NCT04492475, and NCT04640168.
USD (P&R) also shared that “the [expanded access treatment] protocol enrolled a total of 40 patients between March 26, 2020 to September 10, 2020.” According to USD (P&R), only one patient died. Interestingly, this does not account for the 600 other service members and veterans noted with The Remdesivir Papers who were treated with remdesivir and died. Clearly, hundreds were subjected to the use of remdesivir outside the realm of the expanded access treatment protocol and this is the information now being sought by the author.
Remdesiver was definitely a killer. That’s why they used it.